Premium
Preparation of murine B7.1‐glycosylphosphatidylinositol and transmembrane‐anchored staphylococcal enterotoxin
Author(s) -
Yi Pingyong,
Yu Hai,
Ma Wenxue,
Wang Qingqing,
Minev Boris R.
Publication year - 2005
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.20943
Subject(s) - immune system , enterotoxin , t cell , flow cytometry , biology , cancer research , microbiology and biotechnology , medicine , immunology , escherichia coli , biochemistry , gene
BACKGROUND The authors have previously reported a tumor cell vaccine modified with superantigen staphylococcal enterotoxin A (SEA) and its antitumor effect. The tumor cell vaccines modified with multiple immune activators frequently elicited stronger immune responses against established tumors than single‐modified vaccines. METHODS The authors explored the effectiveness of a tumor cell vaccine transduced with immune activators, dual‐modified using the protein transfer technique. First, a glycosylphosphatidylinositol (GPI)‐anchored murine B7.1 (mB7.1‐GPI) and a transmembrane‐anchored SEA (TM‐SEA) were genetically generated. Then, the murine lymphoma EL4 cells were dual modified with the incorporation of mB7.1‐GPI and TM‐SEA onto the cell surface. Flow cytometry and laser confocal microscopy showed that the incorporation of B7.1 and SEA molecules onto EL4 cells was quite stable. RESULTS The dual‐modified tumor cell vaccine EL4/mB7.1‐GPI + TM‐SEA elicited significantly stronger antitumor immune responses both in vitro and in vivo when compared with the single‐modified tumor cell vaccines EL4/mB7.1‐GPI and EL4/TM‐SEA. CONCLUSIONS The results of the current study validated the novel approach for preparing tumor cell vaccines modified with dual immune active molecules using the protein transfer technique, and supported the feasibility and effectiveness of the dual‐modified tumor cell vaccine. Cancer 2005. © 2005 American Cancer Society.